vs
Custom Truck One Source, Inc.（CTOS）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Custom Truck One Source, Inc.的季度营收约是Orthofix Medical Inc.的1.9倍（$422.2M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -4.2%，领先3.2%），Orthofix Medical Inc.同比增速更快（2.0% vs -8.5%），过去两年Custom Truck One Source, Inc.的营收复合增速更高（14.8% vs 8.0%）
Custom Truck One Source是北美领先的专用重型卡车及设备解决方案提供商，业务覆盖定制车辆制造、设备销售与租赁、售后配件供应及维保服务，主要服务基建、公用事业、建筑、能源等核心领域。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
CTOS vs OFIX — 直观对比
营收规模更大
CTOS
是对方的1.9倍
$219.9M
营收增速更快
OFIX
高出10.5%
-8.5%
净利率更高
OFIX
高出3.2%
-4.2%
两年增速更快
CTOS
近两年复合增速
8.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $422.2M | $219.9M |
| 净利润 | $-17.8M | $-2.2M |
| 毛利率 | 20.3% | 71.1% |
| 营业利润率 | 2.9% | 0.2% |
| 净利率 | -4.2% | -1.0% |
| 营收同比 | -8.5% | 2.0% |
| 净利润同比 | -333.7% | 92.4% |
| 每股收益（稀释后） | $-0.08 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTOSOFIX
| Q1 26 | $422.2M | — | ||
| Q4 25 | $387.3M | $219.9M | ||
| Q3 25 | $359.9M | $205.6M | ||
| Q2 25 | $392.2M | $203.1M | ||
| Q1 25 | $307.1M | $193.6M | ||
| Q4 24 | $398.3M | $215.7M | ||
| Q3 24 | $337.5M | $196.6M | ||
| Q2 24 | $320.6M | $198.6M |
净利润CTOSOFIX
| Q1 26 | $-17.8M | — | ||
| Q4 25 | $20.9M | $-2.2M | ||
| Q3 25 | $-5.8M | $-22.8M | ||
| Q2 25 | $-28.4M | $-14.1M | ||
| Q1 25 | $-17.8M | $-53.1M | ||
| Q4 24 | $27.6M | $-29.1M | ||
| Q3 24 | $-17.4M | $-27.4M | ||
| Q2 24 | $-24.5M | $-33.4M |
毛利率CTOSOFIX
| Q1 26 | 20.3% | — | ||
| Q4 25 | 31.8% | 71.1% | ||
| Q3 25 | 28.0% | 72.2% | ||
| Q2 25 | 26.1% | 68.7% | ||
| Q1 25 | 27.9% | 62.8% | ||
| Q4 24 | 29.7% | 69.0% | ||
| Q3 24 | 27.2% | 68.7% | ||
| Q2 24 | 27.8% | 67.8% |
营业利润率CTOSOFIX
| Q1 26 | 2.9% | — | ||
| Q4 25 | 13.4% | 0.2% | ||
| Q3 25 | 9.1% | -8.3% | ||
| Q2 25 | 7.1% | -7.9% | ||
| Q1 25 | 4.0% | -25.2% | ||
| Q4 24 | 16.9% | -5.3% | ||
| Q3 24 | 6.8% | -9.6% | ||
| Q2 24 | 5.5% | -12.5% |
净利率CTOSOFIX
| Q1 26 | -4.2% | — | ||
| Q4 25 | 5.4% | -1.0% | ||
| Q3 25 | -1.6% | -11.1% | ||
| Q2 25 | -7.2% | -6.9% | ||
| Q1 25 | -5.8% | -27.4% | ||
| Q4 24 | 6.9% | -13.5% | ||
| Q3 24 | -5.2% | -13.9% | ||
| Q2 24 | -7.6% | -16.8% |
每股收益（稀释后）CTOSOFIX
| Q1 26 | $-0.08 | — | ||
| Q4 25 | $0.10 | $-0.05 | ||
| Q3 25 | $-0.03 | $-0.57 | ||
| Q2 25 | $-0.13 | $-0.36 | ||
| Q1 25 | $-0.08 | $-1.35 | ||
| Q4 24 | $0.11 | $-0.76 | ||
| Q3 24 | $-0.07 | $-0.71 | ||
| Q2 24 | $-0.10 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.3M | $82.0M |
| 总债务越低越好 | $25.9M | — |
| 股东权益账面价值 | $809.1M | $450.0M |
| 总资产 | $3.4B | $850.6M |
| 负债/权益比越低杠杆越低 | 0.03× | — |
8季度趋势，按日历期对齐
现金及短期投资CTOSOFIX
| Q1 26 | $6.3M | — | ||
| Q4 25 | $6.3M | $82.0M | ||
| Q3 25 | $13.1M | $62.9M | ||
| Q2 25 | $5.3M | $65.6M | ||
| Q1 25 | $5.4M | $58.0M | ||
| Q4 24 | $3.8M | $83.2M | ||
| Q3 24 | $8.4M | $30.1M | ||
| Q2 24 | $8.1M | $26.4M |
总债务CTOSOFIX
| Q1 26 | $25.9M | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | $157.2M | ||
| Q2 25 | $1.6B | $157.0M | ||
| Q1 25 | $1.6B | $156.9M | ||
| Q4 24 | $1.5B | $157.0M | ||
| Q3 24 | $1.6B | $118.5M | ||
| Q2 24 | $1.5B | $118.0M |
股东权益CTOSOFIX
| Q1 26 | $809.1M | — | ||
| Q4 25 | $809.1M | $450.0M | ||
| Q3 25 | $784.7M | $442.5M | ||
| Q2 25 | $790.1M | $458.3M | ||
| Q1 25 | $813.4M | $458.3M | ||
| Q4 24 | $861.3M | $503.1M | ||
| Q3 24 | $837.5M | $525.9M | ||
| Q2 24 | $856.7M | $546.0M |
总资产CTOSOFIX
| Q1 26 | $3.4B | — | ||
| Q4 25 | $3.4B | $850.6M | ||
| Q3 25 | $3.5B | $832.6M | ||
| Q2 25 | $3.6B | $837.2M | ||
| Q1 25 | $3.5B | $823.1M | ||
| Q4 24 | $3.5B | $893.3M | ||
| Q3 24 | $3.6B | $867.9M | ||
| Q2 24 | $3.5B | $882.0M |
负债/权益比CTOSOFIX
| Q1 26 | 0.03× | — | ||
| Q4 25 | 2.03× | — | ||
| Q3 25 | 2.10× | 0.36× | ||
| Q2 25 | 2.04× | 0.34× | ||
| Q1 25 | 1.97× | 0.34× | ||
| Q4 24 | 1.77× | 0.31× | ||
| Q3 24 | 1.87× | 0.23× | ||
| Q2 24 | 1.79× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流CTOSOFIX
| Q1 26 | — | — | ||
| Q4 25 | $47.3M | $27.7M | ||
| Q3 25 | $81.5M | $12.4M | ||
| Q2 25 | $125.7M | $11.6M | ||
| Q1 25 | $55.6M | $-18.4M | ||
| Q4 24 | $82.1M | $23.7M | ||
| Q3 24 | $16.5M | $11.7M | ||
| Q2 24 | $37.8M | $9.0M |
自由现金流CTOSOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | $16.8M | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $-25.1M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $6.3M | ||
| Q2 24 | — | $-360.0K |
自由现金流率CTOSOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 1.2% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | -13.0% | ||
| Q4 24 | — | 7.0% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | — | -0.2% |
资本支出强度CTOSOFIX
| Q1 26 | — | — | ||
| Q4 25 | — | 4.9% | ||
| Q3 25 | — | 4.8% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 3.5% | ||
| Q4 24 | — | 4.0% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 4.7% |
现金转化率CTOSOFIX
| Q1 26 | — | — | ||
| Q4 25 | 2.27× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.98× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTOS
| Equipment sales | $273.9M | 65% |
| Rental revenue | $116.3M | 28% |
| Parts sales and services | $32.1M | 8% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
